Cholecalciferol + risedronate sodium is under clinical development by Dongkook Pharmaceutical and currently in Phase I for Osteoporosis. According to GlobalData, Phase I drugs for Osteoporosis have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cholecalciferol + risedronate sodium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cholecalciferol + risedronate sodium overview
DKF-335 is under development for the treatment of osteoporosis and post menopausal osteoporosis. The drug candidate is a combination of cholecalciferol (vitamin D3) and risedronate sodium. It is administered by the oral route and is formulated as an effervescent tablet. The drug candidate is an incrementally modified drug. Risedronate acts by targeting farnesyl pyrophosphate synthase and cholecalciferol acts by targeting vitamin D receptor. It is administered through oral route.
It was also under development for the treatment of ulcers.
Dongkook Pharmaceutical overview
Dongkook Pharmaceutical (Dongkook) develops, manufactures and distributes pharmaceutical products. The company’s products include prescription drugs, nonprescription drugs, generic drugs, quasi-drugs, medical devices, active pharmaceutical ingredients and cosmetics. It’s pipeline products include DKF-310, DKM-413, DKM-412, DKF-313, DKF-340, DKF-361, DKF-363, DKF-325, DKF-334, DKF-335 and DKM-420. The company’s pipeline treats obesity, diabetes, dementia, osteoarthritis, benign prostatic hyperplasia, hypertension and respiratory inflammation. It provides products under the brand names Insadol Plus, Madecassol, Feramine Q, Sencia, Pansidil, Chisen, Karitopoten and Oramedi, among others. Dongkook is headquartered in Gangnam-gu, Seoul, South Korea.
For a complete picture of Cholecalciferol + risedronate sodium’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
